Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for Gram-Negative rods

Journal of Basic Microbiology

Volumn 53, Issue 4, 2013, Pages 336-339

  Farmer, Aaron R ^a   Murray, Clinton K ^a,b   Mende, Katrin ^a,b   Akers, Kevin S ^a,b   Zera, Wendy C ^a,b   Beckius, Miriam L ^a   Yun, Heather C ^a,b  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Antimicrobial susceptibilities; Gram negative rod; HMG CoA reductase inhibitors

Indexed keywords

ANTIINFECTIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; DRUG EFFECT; DRUG INTERACTION; GRAM NEGATIVE AEROBIC RODS AND COCCI; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; GRAM-NEGATIVE AEROBIC RODS AND COCCI; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROBIAL SENSITIVITY TESTS;

ACINETOBACTER BAUMANNII; ESCHERICHIA COLI; FUNGI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 84876439850     PISSN: 0233111X     EISSN: 15214028     Source Type: Journal    
DOI: 10.1002/jobm.201100614     Document Type: Article

References (18)

1. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E. et al., 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Disease Society of America. Clin. Infect. Dis., 48, 1-12.
2. Janda, S., Young, A., Fitzgerald, J.M., Etminan, M., Swiston, J., 2010. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J. Crit. Care, 25, 656 e7-e22.
3. Tleyjeh, I. M., Kashour, T., Hakim, F.A., 2009. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch. Intern. Med., 18, 1658-1667.
4. Liappis, A.P., Kan, V.L., Rochester, C.G., Simon, G.L., 2001. The effect of statins on mortality in patients with bacteremia. Clin. Infect. Dis., 33, 1352-1357.
5. Terblanche, M., Almog, Y., Rosenson, R., Smith, T., Hackam, D., 2006. Statins: Panacea for sepsis? Lancet Infect. Dis., 6, 242-248.
6. Bergman, P., Linde, C., Putsep, K., Normark, S. et al., 2011. Studies on the antibacterial effects of statins - in vitro and in vivo. PLoS One. 6 8, e24394.
7. Coban, A.Y., Tekeli, H.O., Guney, A.K., Durupinar, B., 2010. Investigation of the in vitro antibacterial effects of statins. Mikrobiol. Bul., 44, 161-163.
8. Jerwood, S., Cohen, J., 2008. Unexpected antimicrobial effect of statins. J. Antimicrob. Chemother., 61, 362-364.
9. Nyilasi, L., Kocsube, S., Krizsan, K., Galgoczy, L. et al., 2010. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol. Lett., 307, 175-184.
10. Pradines, B., Torrentino-Madamet, M., 2007. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob. Agents Chemother., 51, 2654-2655.
11. Wilding, E.L., Kim, D.Y., Bryant, A.P., Gwynn, M.N. et al., 2000, Essentiality, expression and characterization of the class II 3-hydroxy-3-methylglutaryl coenzyme A reductase of Staphylococcus aureus, J. Bacteriol., 182, 5147-5152.
12. Chin, N.X., Weitzman, I., Della-Latta, P., 1997. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother., 41, 850-852.
13. Chamilos, G., Lewis, R.E., Kontoyiannis, D.P., 2006. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob. Agents Chemother., 50, 96-103.
14. Qiao, J., Kontoyiannis, D.P., Wan, Z., Li, R., Liu, W., 2007. Antifungal activity of statins against Aspergillus species. Med. Mycol., 45, 589-593.
15. Hawley, J.S., Murray, C.K., Griffith, M.E., McElmeel, M.L. et al., 2007. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob. Agents Chemother., 51, 376-378.
16. Wikler, M.A., 2009. Clinical Laboratory and Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Keen, E.F., Murray, C.K., Robinson, B.J., Hospenthal, D.R. et al., 2010. Changes in the incidences of multidrug-resistant and extensively drug-resistant organisms isolated in a military medical center. Infect. Control Hosp. Epidemiol., 31, 728-732.
18. Friesen, J.A., Rodwell, V.W., 2004. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol., 5, 248.